Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer

J. H. Park, D. C. McMillan, J. Edwards, P. G. Horgan, and C. S. D. Roxburgh

Academic Unit of Surgery, School of Medicine, University of Glasgow, Royal Infirmary, Glasgow, United Kingdom; Unit of Experimental Therapeutics, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, United Kingdom

ABSTRACT

The aim of the present study was to compare the clinical utility of two measures of the inflammatory cell infiltrate — a H&E-based assessment of the generalized inflammatory cell infiltrate (the Klintrup-Mäkinen (KM) grade), and an immunohistochemistry-based assessment of combined CD3+ and CD8+ T-cell density (the “Immunoscore”), in conjunction with assessment of the tumor stroma percentage (TSP) in patients undergoing resection of stage I-III colorectal cancer (CRC). Two hundred and forty-six patients were identified from a prospectively maintained database of CRC resections in a single surgical unit. Assessment of KM grade and TSP was performed using full H&E sections. CD3+ and CD8+ T-cell density was assessed on full sections and the Immunoscore calculated. KM grade and Immunoscore were strongly associated (p < 0.001). KM grade stratified cancer-specific survival (CSS) from 88% to 66% (p = 0.002) and Immunoscore from 93% to 61% (p < 0.001). Immunoscore further stratified survival of patients independent of KM grade from 94% (high KM, Im4) to 60% (low KM, Im0/1). Furthermore, TSP stratified survival of patients with a weak inflammatory cell infiltrate (low KM: from 75% to 47%; Im0/1: from 71% to 38%, both p < 0.001) but not those with a strong inflammatory infiltrate. On multivariate analysis, only Immunoscore (HR 0.44, p < 0.001) and TSP (HR 2.04, p < 0.001) were independently associated with CSS. These results suggest that the prognostic value of an immunohistochemistry-based assessment of the inflammatory cell infiltrate is superior to H&E-based assessment in patients undergoing resection of stage I-III CRC. Furthermore, assessment of the tumor-associated stroma, using TSP, further improves prediction of outcome.

Abbreviations: H&E, haematoxylin and eosin; KM, Klintrup–Mäkinen; TSP, tumor stroma percentage

Introduction

Colorectal cancer is the second most common cause of cancer death in the United Kingdom and Europe. Following potentially curative surgery, prognosis and the need for adjuvant therapy is primarily based on pathological assessment of the depth of invasion of the primary tumor and the presence of lymphatic and distant organ metastases. However, this TNM-based staging may fail to accurately stage all patients, and in particular those with earlier stage, lymph node negative disease, where other tumor characteristics may identify patients at increased risk and who may benefit from adjuvant treatment.

In addition to such tumor-based characteristics, assessment of the tumor microenvironment may similarly inform prognosis. For example, it is now accepted that the host local inflammatory response is an important determinant of disease progression and oncological outcome in patients with colorectal cancer, with the presence of a conspicuous inflammatory cell infiltrate identified as an independent predictor of improved survival. Histopathological assessment of the density of the generalized inflammatory cell infiltrate using routine pathological specimens has been validated as a stage-independent prognostic characteristic, the prognostic value of immunohistochemistry-based assessment of immune cell type and location within the tumor microenvironment, such as the Immunoscore, has been of interest. Although initially describing the density of cytotoxic (CD8+) and memory (CD45R0+) T-lymphocytes within the tumor microenvironment, the Immunoscore has recently been refined to reflect a cumulative score based on the density of the overall mature CD3+ T-lymphocyte population in addition to the CD8+ T-lymphocyte population within the tumor invasive margin and tumor core, and has been validated as a prognostic marker with superior prognostic ability compared to TNM staging in colorectal cancer. However, whether the Immunoscore is superior to the Klintrup–Mäkinen (KM) assessment of the generalized inflammatory cell infiltrate remains to be determined.

Together with the inflammatory cell infiltrate, the tumor-associated stroma has also been characterized as an important
determinant of disease progression in colorectal cancer.\textsuperscript{11} In particular, assessment of the proportion of stroma, or TSP, within the tumor microenvironment has been shown to predict survival independent of TNM stage for patients undergoing potentially curative resection of colorectal cancer as well as other cancers.\textsuperscript{12-16} Furthermore, in patients with colorectal cancer, TSP has been shown to hold prognostic value independent of the inflammatory cell infiltrate as assessed using the KM grade.\textsuperscript{15} Indeed, combined assessment of KM grade and TSP, termed the Glasgow Microenvironment Score (GMS), stratified survival greater than either measure alone, and in particular further stratified survival of those patients with a weak local inflammatory cell infiltrate.\textsuperscript{17} However, whether inclusion of a potentially more detailed measure of the inflammatory cell infiltrate, such as the Immunoscore, may alter the prognostic value of the tumor-associated stroma is not clear. Therefore, the present study of patients undergoing potentially curative resection of stage I-III colorectal cancer has two aims: to compare the prognostic value of assessment of the inflammatory cell infiltrate using the KM grade and the Immunoscore, and to examine the clinical utility of combined assessment of the inflammatory cell infiltrate and TSP.

**Patients and methods**

**Patients and clinicopathological characteristics**

Patients were identified from a prospectively collected database of all elective and emergency colorectal cancer resections performed in a single surgical unit in Glasgow Royal Infirmary since 1997. For the purposes of the present study, patients who had undergone primary resection between 1997 and 2008 for stage I-III colorectal cancer were included. Patients who had undergone localized or endoscopic resection, surgery with palliative intent, neoadjuvant chemoradiotherapy or who had died within 30 d of surgery were excluded. Only patients with rectal cancer who, after discussion at local colorectal multidisciplinary meetings comprised of colorectal surgeons, pathologists, radiologists and oncologists, were deemed to not require neoadjuvant therapy prior to curative surgery were included. Approval was obtained from the West of Scotland Ethics Committee.

Pathological staging was performed according to the TNM 5th edition.\textsuperscript{5} Venous invasion was identified using elastica staining as has been routine in our department since 2003; patients who had undergone resection prior to 2003 underwent retrospective reporting of venous invasion with elastica staining. Patients were routinely discussed at local colorectal cancer multidisciplinary meetings following resection; patients with stage III disease or high-risk stage II disease were considered for adjuvant chemotherapy when not precluded by advanced age, significant co-morbidity, or patient preference. Use of anti-angiogenic and anti-EGFR inhibitors was not routine during the study period.

The systemic inflammatory response, a stage-independent predictor of survival in patients with colorectal cancer, was reported using the modified Glasgow Prognostic Score (mGPS) as previously described.\textsuperscript{18} Briefly, patients with serum C-reactive protein (CRP) ≤ 10mg/L were given a score of 0, patients with CRP > 10mg/L and serum albumin ≥ 35g/L a score of 1, and patients with CRP > 10mg/L and albumin < 35g/L a score of two. Serum CRP and albumin were recorded within 30 d prior to surgery for patients undergoing elective resection and on admission for patients undergoing emergency resection.

**Assessment of the tumor microenvironment**

The generalized inflammatory cell infiltrate was assessed using the KM score as previously described.\textsuperscript{6} Briefly, hematopoietic and eosin-stained (H&E) section of the deepest point of tumor invasion were retrieved and the generalized inflammatory cell infiltrate at the invasive margin assessed in a semi-quantitative fashion using a 4-point scale (0- no increase, 1- mild or patchy increase in inflammatory cells, 2- prominent inflammatory reaction forming a band at the invasive margin, and 3- florid cup-like infiltrate at the invasive edge with destruction of cancer cell islands). For the purposes of statistical analysis, patients were subsequently classified as low grade (0/1) or high grade (2/3) response (Fig. 1A, B).

Full sections of the invasive margin were stained using antibodies for CD3\textsuperscript{+}, a mature T-lymphocyte marker, and CD8\textsuperscript{+}, a marker of cytotoxic T-lymphocytes, as previously described.\textsuperscript{19} The Immunoscore was then calculated as previously described.\textsuperscript{8,19} Briefly, the density of CD3\textsuperscript{+} and CD8\textsuperscript{+} T-cells within the invasive margin and tumor center were separately semi-quantitatively graded as high or low; the Immunoscore was calculated from the number of regions with a high CD3\textsuperscript{+} and CD8\textsuperscript{+} cell density, giving five potential groups (Im0, Im1, Im2, Im3, Im4), ranging from all regions low density (Im0) to all regions high density (Im4).

TSP was examined as previously described.\textsuperscript{15} Briefly, using H&E sections of the invasive margin, TSP was calculated as the percentage of the visible field comprised of stroma, excluding areas of necrosis and mucin deposition. Patients were graded as either low (<50%) or high TSP (>50%) (Fig. 1C, D).

All assessments of the tumor microenvironment were performed by a single investigator blinded to clinical outcomes with co-scoring of at least 10% to ensure consistency of scoring. As previously reported, the intra-class correlation coefficient was greater than 0.8 for all assessments, indicating excellent agreement (KM grade – 0.83; CD3\textsuperscript{+} margin – 0.83; CD3\textsuperscript{+} center – 0.87; CD8\textsuperscript{+} margin – 0.83; CD8\textsuperscript{+} center – 0.87)\textsuperscript{6,13,19}

**Survival**

Following resection patients were routinely followed-up for five years according to local treatment and surveillance guidelines. Date and cause of death were crosschecked with the cancer registration system and the Registrar General (Scotland). CSS was measured in months as the date from surgery until date of death from recurrent or metastatic colorectal cancer. Death records were complete until March 31, 2014, which acted as the censor date.
Statistical analysis

The relationship between components of the tumor microenvironment and CSS was examined using Kaplan–Meier log-rank analysis, with five-year survival presented as percentage surviving (standard error). The relationship between components of the tumor microenvironment, clinicopathological characteristic and survival was examined using multivariate Cox proportional hazards regression to calculate hazard ratios (HR) and 95% confidence intervals (CI). Variables with a p-value ≤0.05 on univariate regression analysis were entered into a multivariate model using a backward conditional approach. All statistical analyses were performed using SPSS version 22.0 (IBM SPSS). A p-value ≤ 0.05 was considered statistically significant.

Results

The study population was comprised of 246 patients undergoing potentially curative resection of stage I-III colorectal cancer. Clinicopathological characteristics are displayed in Table 1. Approximately two-thirds of patients were 65 y of age or older at time of surgery and 52% were male. Fifteen patients (6%) underwent emergency resection, and just over two-thirds of patients underwent resection of colon cancer. Histopathological reporting confirmed stage I, stage II and stage III disease in 7%, 52% and 41% of patients respectively. Mismatch repair status has previously been reported in a subset of this cohort and was available for 205 patients;17 30 patients (15%) had mismatch repair deficient colorectal cancer.

The mean follow-up of survivors was 150 mo (range 87–206 mo) with 76 colorectal cancer-related deaths and 76 non-cancer deaths. Mean and 5-y survival was 40 mo and 74% for CSS, and 79 mo and 63% for overall survival. In total, 71 patients (29%) received adjuvant chemotherapy; 1 patient with stage I (6%) disease, 19 patients with stage II disease (15%), and 51 patients with stage III disease (51%) received adjuvant chemotherapy. Compared to patients who did not receive adjuvant therapy, patients with node negative (stage I/II) disease who received adjuvant chemotherapy were younger (p = 0.004), more likely to have venous invasion (p = 0.009), margin involvement (p = 0.045) or peritoneal involvement (p = 0.046) and showed a trend toward emergency presentation (p = 0.078) and poor tumor differentiation (p = 0.062). Patients receiving adjuvant chemotherapy showed a non-significant trend toward poorer survival (p = 0.158); patients with node negative (stage I/II) disease receiving adjuvant therapy showed a trend toward poorer five-year survival (69% vs. 85%; p = 0.196), whereas patients with node positive (stage III) disease receiving adjuvant therapy showed a trend toward increased five-year survival (69% vs. 51%; p = 0.153).

Relationship between local inflammatory cell infiltrate and cancer-specific survival

The relationship between the inflammatory cell infiltrate and CSS is displayed in Fig. 2. The KM score was associated with
| Characteristic                              | n (%)                  |
|--------------------------------------------|------------------------|
| Age (<65/65-74/75)                         | 82 (33) / 84 (34) / 80 (33) |
| Sex (female/male)                          | 117 (48) / 129 (52)    |
| Presentation (elective/emergency)          | 231 (94) / 15 (6)      |
| Adjuvant therapy                           | 175 (51) / 71 (29)     |
| Tumor site (colon/rectum)                  | 169 (69) / 77 (31)     |
| TNM stage (I/II/III)                       | 18 (7) / 128 (52) / 100 (41) |
| T stage (1-2/3/4)                           | 26 (11) / 152 (62) / 68 (28) |
| N stage (0/1/2)                             | 146 (59) / 77 (31) / 23 (9) |
| LN examined (>12/<12)                      | 159 (65) / 87 (35)     |
| Differentiation (mod-well/poor)            | 216 (88) / 30 (12)     |
| Venous invasion (no/yes)                   | 158 (64) / 88 (36)     |
| Margin involvement (no/yes)                | 230 (94) / 16 (7)      |
| Peritoneal involvement (no/yes)            | 178 (72) / 68 (28)     |
| Tumor perforation (no/yes)                 | 238 (97) / 8 (3)       |
| Mismatch repair status (competent/deficient) | 175 (85) / 30 (15)  |
| Tumor stroma percentage (low/high)         | 179 (73) / 67 (27)     |
| Klintrup–Mäkinen score (0/1/2/3)           | 50 (20) / 111 (45) / 64 (26) / 21 (9) |
| Klintrup–Mäkinen grade (low/high)          | 161 (65) / 75 (35)     |
| Immunoscore (0/1/2/3/4)                    | 87 (35) / 40 (16) / 44 (18) / 43 (18) / 32 (13) |
| Alive/cancer death/non-cancer death         | 94 (38) / 76 (31) / 76 (31) |

*Data not available for 41 patients.

Figure 2. Relationship between tumor inflammatory cell infiltrate and cancer-specific survival of patients undergoing potentially curative resection of stage I-III colorectal cancer (A) Klintrup–Mäkinen score ($p = 0.015$), (B) Klintrup–Mäkinen grade ($p = 0.002$), (C) Immunoscore ($p < 0.001$), and (D) Immunoscore stratified in to three groups ($p < 0.001$).
CSS \((p = 0.015; \text{Fig. 1A})\). When classified as low grade or high grade, a low KM grade was associated with poorer five-year survival \((66\% \text{ vs. } 88\%; p = 0.002; \text{Fig. 1B})\). When stratified by tumor site (Table S1, Fig. S1), low KM grade was associated with poorer survival in patients with colon cancer \((p < 0.05)\) and showed a trend toward poorer survival in patients with rectal cancer \((p = 0.068)\). When stratified by TNM stage, low KM grade showed a trend toward poorer survival in patients with node negative (TNM I/II) disease \((p = 0.053)\) and node positive (TNM III) disease \((p = 0.057)\). Finally, low KM grade was associated with poorer survival in both patients who did not receive and who received adjuvant chemotherapy (both \(p < 0.05\)).

A decrease in Immunoscore was associated with a decrease in CSS (Fig. 1C): five-year CSS ranged from 93% for patients with an Immunoscore = 4 to 61% for patients with an Immunoscore = 0 \((p < 0.001)\). The survival of patients with Im0 and Im1, or Im2 and Im3 did not differ significantly \((p = 0.788 \text{ and } p = 0.599, \text{respectively})\). As such, for further statistical analysis the Immunoscore was refined to stratify patients in to three prognostic groups (Fig. 1D): Im4, with five-year survival of 93%; Im2/3, with five-year survival of 84%; and Im0/1, five-year survival of 61% \((p < 0.001)\). When stratified by tumor site or TNM stage (Table S1, Fig. S2), the Immunoscore was associated with survival of patients with both colon and rectal cancer \((p < 0.01)\) and of patients with both node negative \((p < 0.01)\) and node positive \((p < 0.05)\) disease. Finally, low Immunoscore was associated with poorer survival in patients who did not receive adjuvant chemotherapy \((p < 0.001)\) and showed a trend toward poorer survival in patients who did receive adjuvant therapy \((p = 0.059)\).

The KM grade was strongly associated with the Immunoscore \((p < 0.001; \text{Fig. 3})\), however neither KM grade nor Immunoscore were associated with mismatch repair status \((p = 0.661 \text{ and } p = 0.284 \text{ respectively})\) or the systemic inflammatory response as measured by mGPS \((p = 0.999 \text{ and } p = 0.214 \text{ respectively})\). Comparison between the prognostic value of the KM grade and Immunoscore was subsequently performed (Table 2). The KM grade stratified five-year CSS from 88% (high grade) to 66% and the Immunoscore stratified survival from 93% to 61%. The Immunoscore was able to further stratify the survival of patients with both a low and high KM grade; the survival of patients with a low grade KM ranged from 90% (Im4) to 60% (Im0/1) \((p = 0.015)\), whereas the survival of patients with a high grade KM ranged from 94% (Im4) to 71% (Im0/1) \((p = 0.010)\). In contrast, the KM grade did not further significantly stratify the Immunoscore.

### Table 2. Relationship between Immunoscore, Klintrup–Mäkinen grade and cancer-specific survival of patients undergoing potentially curative resection of stage I-III colorectal cancer.

| Immunoscore | Low grade KM | High grade KM | All KM |
|-------------|--------------|---------------|--------|
|             | n            | 5-y CSS       | n      | 5-y CSS       | n      | 5-y CSS       |
| Im0/1       | 108          | 60% (5)       | 19     | 71% (11)      | 127    | 61% (4)       |
| Im2/3       | 42           | 77% (7)       | 45     | 91% (4)       | 87     | 84% (4)       |
| Im4         | 11           | 90% (9)       | 21     | 94% (5)       | 32     | 93% (5)       |
| All (Im0-4) | 161          | 66% (4)*      | 85     | 88% (4)*      | 246    | 74% (3)       |

Survival displayed as five-year cancer-specific survival (standard error)

*Log-rank survival analysis \(p < 0.05\)

KM – Klintrup-Mäkinen, CSS – cancer-specific survival

### Relationship between tumor stroma percentage, the tumor inflammatory cell infiltrate and cancer-specific survival

The prognostic value of combined assessment of the inflammatory cell infiltrate and TSP was subsequently examined (Table 3). The TSP significantly stratified the survival of patients from 80% (low TSP) to 57% (high TSP) \((p = 0.001)\). In combination with the inflammatory cell infiltrate, TSP significantly stratified survival of those with a weak infiltrate but not those with a strong infiltrate. In particular, TSP significantly stratified survival of patients with a low KM grade from 75% to 47% \((p < 0.001)\), whereas in patients with a high KM grade, survival of patients with a low TSP was comparable to that of patients with a high TSP \((p = 0.485)\). In combination with the Immunoscore, the effect of TSP on survival decreased as the Immunoscore increased; TSP stratified the survival of patients with Im0/1 from 71% to 38% \((p < 0.001)\) and patients with Im2/3 from 87% to 77% \((p = 0.069)\), but not patients with Im4 \((p = 0.545)\) (Fig. 4). Conversely, assessment of the inflammatory cell infiltrate was able to stratify survival of patients with both a high and low TSP; KM grade stratified patients with a low TSP from 88% to 75% \((p = 0.081)\) and patients with a high TSP from 87% to 47% \((p = 0.034)\), whereas Immunoscore stratified survival of patients with a low TSP from 92% to 71% \((p = 0.002)\) and patients with a high TSP from 100% to 38% \((p = 0.004)\).

### Relationship between the tumor microenvironment, clinicopathological characteristics and cancer-specific survival

On univariate survival analysis (Table 4), emergency presentation, T stage, mGPS (both \(p < 0.05\)), N stage, venous invasion,
margin involvement and peritoneal involvement (all \( p < 0.001 \)) were associated with CSS. The KM grade \( (p = 0.003) \), Immunoscore and TSP were all associated with survival (both \( p < 0.001 \)).

On multivariate analysis, after controlling for age, sex, tumor site and adjuvant therapy and considering all variables significant on univariate analysis, the Immunoscore and TSP were all associated with survival (both \( p < 0.01 \)).

On multivariate analysis, after controlling for age, sex, tumor site and adjuvant therapy and considering all variables significant on univariate analysis, the Immunoscore and TSP were all associated with survival (both \( p < 0.01 \)).

Survival displayed as five-year cancer-specific survival (standard error).

- \( ^{a} p < 0.05 \)
- \( ^{b} p < 0.01 \)
- \( ^{c} p < 0.001 \). KM- Klintrup–Mäkinen, TSP- tumor stroma percentage, CSS- cancer-specific survival.

### Discussion

In the present study, an immunohistochemistry-based assessment of the inflammatory cell infiltrate was superior to that of H&E-based assessment in predicting outcome of patients undergoing potentially curative resection of stage I-III colorectal cancer. Furthermore, the combination of assessment of the inflammatory cell infiltrate, using either KM grade or

### Table 3. Relationship between measures of the local inflammatory cell infiltrate, tumor stroma percentage and cancer-specific survival of patients undergoing potentially curative resection of stage I-III colorectal cancer.

| KM                | Low grade | High grade | All KM |
|-------------------|-----------|------------|--------|
| TSP               | \( n \)   | 5-y CSS    | \( n \)  |
| High              | 50        | 47% (7)    | 67     |
| Low               | 111       | 68% (4)    | 179    |
| All               | 161       | 66% (4)    | 246    |

| KM                | Low grade | High grade | All KM |
|-------------------|-----------|------------|--------|
| TSP               | \( n \)   | 5-y CSS    | \( n \)  |
| High              | 50        | 47% (7)    | 67     |
| Low               | 111       | 68% (4)    | 179    |
| All               | 161       | 66% (4)    | 246    |

| Immunoscore       | Im0/1     | Im2/3      | Im4    |
|-------------------|-----------|------------|--------|
| Low               | \( n \)   | 5-y CSS    | \( n \)  |
| High              | 50        | 47% (7)    | 67     |
| Low               | 111       | 68% (4)    | 179    |
| All               | 161       | 66% (4)    | 246    |

Survival displayed as five-year cancer-specific survival (standard error).

- \( ^{a} p < 0.05 \)
- \( ^{b} p < 0.01 \)
- \( ^{c} p < 0.001 \). KM- Klintrup–Mäkinen, TSP- tumor stroma percentage, CSS- cancer-specific survival.

Figure 4. Relationship between Immunoscore, tumor stroma percentage and cancer-specific survival in patients undergoing potentially curative resection of stage I-III colorectal cancer (A) Im0/1 \( (p < 0.001) \), (B) Im2/3 \( (p = 0.069) \), (C) Im4 \( (p = 0.545) \).
Immunoscore, and assessment of the tumor-associated stroma, using TSP, provided additional prognostic information.

The present study compared the prognostic utility of two validated measures of the tumor inflammatory cell infiltrate — the KM grade and the Immunoscore.\(^5,8\) Although both were associated with CSS, the Immunoscore, an immunohistochemistry-based assessment of CD3\(^+\) and CD8\(^+\) T-lymphocyte density, was able to better stratify survival of patients than the KM grade, an H&E-based assessment of the generalized inflammatory cell infiltrate. In particular, the Immunoscore was able to stratify survival of patients with both a low and high KM grade; indeed, survival of patients with a low KM grade but high Immunoscore was comparable to that of patients with a high KM grade.

The relative difference in the prognostic value of both measures of the inflammatory cell infiltrate may be explained by the components of the immune response that each measures. Whereas the KM grade provides a measure of the overall, generalized inflammatory cell infiltrate, the Immunoscore measures the host adaptive T-lymphocytic response to cancer. Indeed, although an increase in KM grade is associated with an increase in the density of tumor-infiltrating T-lymphocytes,\(^19-21\) it is also associated with an increase in the density of the innate immune infiltrate, and in particular neutrophils and macrophages.\(^20,21\) For example, in the present study, within the group of patients with a high KM grade, the number of patients with a low (Im0/1, \(n = 19\)) or high (Im4, \(n = 21\)) Immunoscore was similar, whereas of those patients with a low KM grade, a small number had a high Immunoscore. However, although the importance of host adaptive antitumor immune responses is recognized, it is now appreciated that myeloid-derived cells, such as neutrophils and macrophages, play an important functional role in promoting tumor progression.\(^22\) Indeed, it remains to be determined whether immunohistochemical assessment of the innate immune infiltrate may increase the clinical and prognostic utility of measuring the inflammatory cell infiltrate in patients with colorectal cancer.

It was of interest in the present cohort that TSP, an assessment of the tumor-associated stroma, was associated with survival independent of either measure of the inflammatory cell infiltrate, and that combined assessment provided greater prognostic value. For example, it was possible to stratify five-year survival from 92% (Im4, low TSP) to 38% (Im0/1, high TSP). Furthermore, although the relationship between TSP and survival was strongest in patients with a poor inflammatory cell infiltrate, both the number of patients with a high TSP, and its prognostic value, decreased as the density of the inflammatory infiltrate increased. Although it has previously been suggested that the presence of a tumor-associated stroma precludes effective infiltration of the tumor microenvironment by an anti-tumor immune response,\(^23\) the present results are consistent with our previous findings,\(^17\) and may favor the alternative hypothesis that loss of the adaptive immune infiltrate predisposes to the development of a pro-tumor stromal compartment, potentially mediated by the residual innate immune infiltrate.\(^21,24,25\)

We have previously proposed a novel prognostic score based on assessment of the KM grade and TSP, termed the GMS,\(^17\) however the present results suggest that a similar scheme may be applied to the combination of the Immunoscore and TSP and may have even greater clinical utility. Indeed, such a combination may optimize risk prediction in patients undergoing colorectal cancer resection by identifying both those with an excellent prognosis (Im4; five-year CSS of 93%), and those with an extremely poor prognosis.

| mGPS (0/ 1/ 2) | Univariate HR (95% CI) | p | Multivariate HR (95% CI) (Model 1) | p | Multivariate HR (95% CI) (Model 2) | p |
|----------------|------------------------|---|-----------------------------------|---|-----------------------------------|---|
| Age (<65/ 65–74/ >75) | 1.18 (0.90–1.57) | 0.237 | – | 0.444 | – | 0.091 |
| Sex (female/ male) | 0.93 (0.59–1.46) | 0.762 | – | 0.065 | – | 0.308 |
| Presentation (elective/ emergency) | 2.22 (1.06–4.62) | 0.034 | – | 0.724 | – | 0.369 |
| Adjuvant therapy (no/ yes) | 1.40 (0.88–2.24) | 0.160 | – | 0.988 | – | 0.505 |
| mGPS (0/ 1/ 2) | 1.50 (1.10–2.05) | 0.010 | 1.52 (1.09–2.11) | 0.013 | 1.61 (1.16–2.24) | 0.005 |
| Tumor site (colon/ rectum) | 0.82 (0.49–1.36) | 0.433 | – | 0.479 | – | 0.316 |
| T stage (1–2/ 3/ 4) | 1.49 (1.07–2.07) | 0.017 | – | 0.704 | – | 0.981 |
| N stage (0/ 1/ 2) | 1.78 (1.32–2.41) | <0.001 | – | 0.148 | – | 0.066 |
| Lymph nodes examined (no/ yes) | 1.38 (0.87–2.17) | 0.171 | – | – | – | – |
| Differentiation (mod-well/ poor) | 1.40 (0.72–2.72) | 0.322 | – | – | – | – |
| Venous invasion | 2.95 (1.87–4.66) | <0.001 | 2.20 (1.37–3.54) | 0.001 | 2.35 (1.45–3.80) | 0.001 |
| Margin involvement (no/ yes) | 3.15 (1.56–6.33) | 0.001 | – | 0.067 | – | 0.096 |
| Peritoneal involvement (no/ yes) | 2.19 (1.38–3.46) | 0.001 | – | 0.225 | – | 0.125 |
| Tumor perforation (no/ yes) | 2.52 (0.92–6.93) | 0.072 | – | – | – | 0.060 |
| MMR status (competent/ deficient) | 0.42 (0.17–1.05) | 0.064 | – | – | – | – |
| TSP (low/ high) | 2.46 (1.56–3.89) | <0.001 | 2.36 (1.44–3.84) | 0.001 | 2.05 (1.28–3.30) | 0.003 |
| KM grade (weak/ strong) | 0.44 (0.25–0.76) | 0.03 | – | 0.469 | – | 0.015 |
| Immunoscore classification (Im0/1/ Im2–3/ Im4) | 0.66 (0.56–0.80) | <0.001 | 0.43 (0.28–0.66) | <0.001 | 

---

mGPS – modified Glasgow Prognostic Score, MMR- mismatch repair status, TSP – tumor stroma percentage, KM – Klintrup–Mäkinen.
who may benefit from adjuvant therapy (Im0/1, high TSP; five-year CSS of 38%).

In the present study, it was of interest that both the systemic inflammatory response as measured by mGPS, and the local inflammatory cell infiltrate as measured by KM grade or Immunoscore had independent prognostic value in the multivariate analysis. It is likely that these measures reflect the same underlying process and therefore it would be of interest to compare the local and systemic inflammatory responses and how they may be combined to form a prognostic score. Indeed, Turner and colleagues have recently combined measures of the local and systemic inflammatory response to give better risk stratification in patients with node negative colorectal cancer.26 However, the rationale of their approach that combined the neutrophil:lymphocyte ratio (NLR) and assessment of the chronic inflammatory cell density, was not clear since different cell types were assessed locally and systemically. Indeed, only approximately 20% of patients had an elevated NLR and a low chronic inflammatory cell density, and therefore this score does not capture the same entity. Similarly, combinations of other systemic and local inflammatory measures, such as the mGPS and KM grade or Immunoscore, will have such limitations. Moreover, the numbers of patients included in the present study (n = 246) limits the value of such analysis and therefore was not formally examined.

Of note in the present study, the use of adjuvant chemotherapy was not associated with a significant improvement in survival and, in patients with node negative disease, showed a non-significant trend toward poorer survival. However, given the effect size of adjuvant chemotherapy in patients with node negative disease is modest (3.6% absolute improvement in survival) and, in patients with node negative disease, showed a non-significant trend toward poorer survival. However, given the effect size of adjuvant chemotherapy in patients with node negative disease is modest (3.6% absolute improvement in survival of patients with stage II disease at negative disease is modest (3.6% absolute improvement in survival in five years in the QUASAR trial (n = 2,983)),27 the present study did not have sufficient statistical power to examine the impact of adjuvant chemotherapy on survival of patients with colorectal cancer.

The present study is perhaps limited by its use of manual, semi-quantitative assessment of the inflammatory cell infiltrate as opposed to automated assessment as has been recommended for routine assessment of the Immunoscore.8 However, the manual techniques employed showed excellent inter-operator agreement6,19 and manual assessment of the inflammatory cell infiltrate has been shown to correlate strongly with automated assessment.28,29 Furthermore, manual assessment of immunohistochemical staining may allow for greater discrimination of non-specific, background staining and provide superior prognostic value compared to automated assessment.29 Furthermore, meaningful statistical analysis was precluded by the small number of patients in particular subgroups, such as those with stage II disease and high-risk pathological characteristics, or patients with stage I disease. Finally, the results of the present study, and in particular the prognostic utility of combined assessment of the inflammatory cell infiltrate and tumor-associated stroma, remain to be validated in an independent patient cohort from an independent center.

In conclusion, the present results suggest that the prognostic value of an immunohistochemistry-based assessment of the inflammatory cell infiltrate is superior to H&E-based assessment in patients undergoing potentially curative resection of stage I-III colorectal cancer. Furthermore, TSP improves the prediction of survival by either measure of the inflammatory cell infiltrate.

Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.

Acknowledgments
The authors thank the colorectal surgeons of Glasgow Royal Infirmary for their contribution.

References
1. Ferlay J, Steliarova-Foucher E, Lorerti-Tiulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49:1374-403; PMID:23485231; http://dx.doi.org/10.1016/j.ejca.2012.12.027
2. Fleming ID, American Joint Committee on Cancer, American Cancer Society, et al. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott- Raven; 1997.
3. Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012; 38:451-66; PMID:21945823; http://dx.doi.org/10.1016/j.cvr.2011.09.001
4. Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, Peng H, Cui L, Li C. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 2014; 110:1595-605; PMID:24504370; http://dx.doi.org/10.1038/bjc.2014.46
5. Klintrup K, Makinen JM, Kaupilla S, Vare PO, Melko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ, Makinen MJ. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41:2645-54; PMID:16239109; http://dx.doi.org/10.1016/j.ejca.2005.07.017
6. Roxburgh CS, Salmon JD, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009; 249:788-93; PMID:19387324; http://dx.doi.org/10.1097/SLA.0b013e3181aa645a
7. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
8. Galon J, Mlecnik B, Binion G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122256; http://dx.doi.org/10.1002/path.4287
9. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Binion G, Meachi T, Bruneval P, Trajanoski Z, Fridman WH, Pagés F et al. Histopathology-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425
10. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Binion G, Ferariu D et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res 2014; 20:1891-9; PMID:24691640; http://dx.doi.org/10.1158/1078-0432.CCR-13-2830
11. Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, Melano A, Senetta R, Cassenti A, Sonetto C et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 2015; 47:312-9; PMID:25706627; http://dx.doi.org/10.1038/ng.3224
12. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to
lymph node status and tumor stage. Cell Oncol 2007; 29:387-98; PMID:17726261; http://dx.doi.org/10.1155/2007/175276

13. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol 2014; 25:644-51; PMID:24458470; http://dx.doi.org/10.1093/annonc/mds246

14. Dekker TJ, van de Velde CJ, van Pelt GW, Kroep JR, Julien JP, Smit VT, Tollenaar RA, Mesker WE. Prognostic significance of the tumour-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat 2013; 139:371-9; PMID:23709090; http://dx.doi.org/10.1007/s10549-013-2571-5

15. Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, Junggeburt JM, Spitzer-Naaykens JM, Karsten T, Hartgrink HH, Mesker WE et al. The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer 2013; 49:4672-8; PMID:20044247; http://dx.doi.org/10.1016/j.ejca.2009.12.006

16. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 2013; 24:179-85; PMID:22865778; http://dx.doi.org/10.1093/annonc/mds246

17. Park JH, McMillan DC, Powell AG, Richards CH, Horgan PG, Edwards J, Roxburgh CS. Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer. Clin Cancer Res 2015; 21:882-8; PMID:25473000; http://dx.doi.org/10.1158/1078-0432.CCR-14-1868

18. Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host. Ann Surg 2015; 263:326-36; PMID:25575264; http://dx.doi.org/10.1097/SLA.0000000000001122

19. Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC. The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer 2014; 50:309-19; PMID:24105145; http://dx.doi.org/10.1016/j.ejca.2013.09.008

20. Vayrynen JP, Tuomisto A, Klintrup K, Makela J, Karttunen TJ, Mäkinen MJ. Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer 2013; 109:1839-47; PMID:24008661; http://dx.doi.org/10.1038/bjc.2013.508

21. Richards CH, Flegg KM, Roxburgh CSD, Going JJ, Mohammed Z, Horgan PG, McMillan DC. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 2012; 106:2010-5; PMID:22596238; http://dx.doi.org/10.1038/bjc.2012.211

22. Galdiero MR, Garlanda C, Jallion S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013; 228:1404-12; PMID:23065796; http://dx.doi.org/10.1002/jcp.24260

23. Hartmann N, Giese NA, Giese T, Poschke J, Offringa R, Werner J, Ryschich E. Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer. Clin Cancer Res 2014; 20:3422-33; PMID:24763614; http://dx.doi.org/10.1158/1078-0432.CCR-13-2972

24. Chrysanthopoulou A, Mitroulis I, Apostolidou E, Arellaki S, Mikroulis D, Konstantinidis T, Sivridis E, Koffa M, Giromanolaki A, Boumpas DT et al. Neutrophil extracellular traps promote differentiation and function of fibroblasts. J Pathol 2014; 233:294-307; PMID:24740698; http://dx.doi.org/10.1002/path.4359

25. Park JH, Roxburgh CS, McMillan DC. Comment on 'Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis'. Br J Cancer 2014; 111:2372; PMID:25349973; http://dx.doi.org/10.1038/bjc.2014.296

26. Turner N, Wong HL, Templeton A, Tripathy S, Rogers TW, Croxford M, Jones I, Sinnathamy M, Desai J, Tje J et al. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. Int J Cancer 2016; 138:671-8; PMID:26270488; http://dx.doi.org/10.1002/ijc.29805

27. Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370:2020-9; PMID:18083404; http://dx.doi.org/10.1016/S0140-6736(07)61866-2

28. Forrest R, Guthrie GJ, Orange C, Horgan PG, Mcmillan DC, Roxburgh CS. Comparison of visual and automated assessment of tumour stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat 2013; 139:371-9; PMID:23709090; http://dx.doi.org/10.1007/s10549-013-2571-5

29. De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van VT, Tollenaar RA, Mesker WE et al. The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer 2013; 49:4672-8; PMID:20044247; http://dx.doi.org/10.1016/j.ejca.2009.12.006

30. Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 2013; 24:179-85; PMID:22865778; http://dx.doi.org/10.1093/annonc/mds246

31. Park JH, McMillan DC, Powell AG, Richards CH, Horgan PG, Edwards J, Roxburgh CS. Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer. Clin Cancer Res 2015; 21:882-8; PMID:25473000; http://dx.doi.org/10.1158/1078-0432.CCR-14-1868

32. Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host. Ann Surg 2015; 263:326-36; PMID:25575264; http://dx.doi.org/10.1097/SLA.0000000000001122

33. Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC. The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer 2014; 50:309-19; PMID:24105145; http://dx.doi.org/10.1016/j.ejca.2013.09.008

34. Vayrynen JP, Tuomisto A, Klintrup K, Makela J, Karttunen TJ, Mäkinen MJ. Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer 2013; 109:1839-47; PMID:24008661; http://dx.doi.org/10.1038/bjc.2013.508

35. Richards CH, Flegg KM, Roxburgh CSD, Going JJ, Mohammed Z, Horgan PG, McMillan DC. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 2012; 106:2010-5; PMID:22596238; http://dx.doi.org/10.1038/bjc.2012.211